Boehringer Ingelheim

Boehringer Ingelheim is a global group of companies embracing many cultures and diverse societies. The goals and beliefs of the Boehringer Ingelheim companies' team can be summed up in a single phrase: Value through innovation, the central concept of our corporate vision. Together with the concept of our company culture "Lead & Learn", this vision is the guide of our company culture. Boehringer Ingelheim is one of the world's leading pharmaceutical companies based on our more than 125 years of experience.

Get to know the values ​​that guide us: Care, independence, responsibility and innovation. A clinical trial is a research study to answer specific questions about a new medical treatment (drugs, medical device, new treatments, vaccines), or to find new effective ways of using known treatments. Clinical trials are used to determine whether these new treatments are as safe and effective. THE conducting Boehringer Ingelheim clinical trials and its sponsors to establish the safety and efficacy of the medicines it develops is intended to strengthen our capacity to innovate and encourage scientific creativity for diseases with great unmet medical need.

Why Boehringer Ingelheim

It is based on three pillars:

1. Discovery Therapeutics Research, focusing on key diseases and actively investing early in research, through clinical development and finally to the market phase.
2. Scientific platforms, in which we focus on more dynamic research fields, such as immune differentiation and regenerative medicine, which can influence and create new perspectives in various therapeutic areas.
3. Research Beyond Frontiers, where we explore emerging science and technology, but beyond Therapeutic Research Discovery we prepare a timely and effective launch of emerging new medical and scientific technologies.

With Boehringer Ingelheim's successes in research & development we continuously strengthen the portfolio of medicines to offer patients true therapeutic benefit.

Our strategy focuses on four therapeutic areas of research with great medical need:

• Immunology and diseases of the respiratory system,
• Cardiometabolic diseases,
• Diseases of the central nervous system, and
• Oncology.

Many years of experience in this therapeutic field have allowed us to help the millions of patients suffering from potentially life-threatening cardiovascular and metabolic diseases. THE research and development has led us to significant achievements over the past few years, especially in thromboembolic diseases and type 2 diabetes.

Our current research efforts focus on novel strategies for the treatment of diabetes, obesity, non-alcoholic steatohepatitis (NASH), diabetic retinopathy, and chronic kidney disease. Together these therapies complement each other to reduce the risk of cardiovascular morbidity and mortality.

About 300 scientists work in our fully integrated drug discovery center .

At Boehringer Ingelheim, research and development takes place in three major research & development areas (Ridgefield, USA, Biberach, Germany and Vienna, Austria) and two support centers (Kobe, Japan and Milan, Italy).

Over the past decade clinical research has been conducted in 87 countries around the world where it has been shown that people with the best scientific and technological knowledge, flexible thinking and good communication, who work well with their peers inside and outside the company can guarantee success in research and development.

Our vision "Value through Innovation" is the driving force behind drug discovery worldwide - sites - research and development. In addition to the development of substances prominent in research for the treatment of cardiovascular, central nervous system, respiratory, urological and virological disorders, research has also progressed successfully in oncological, metabolic and thromboembolic diseases.